OMGA vs. VIGL, LIFE, SGMO, BLUE, KPTI, DBVT, GRTS, VXRT, OTLK, and MOLN
Should you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), Karyopharm Therapeutics (KPTI), DBV Technologies (DBVT), Gritstone bio (GRTS), Vaxart (VXRT), Outlook Therapeutics (OTLK), and Molecular Partners (MOLN). These companies are all part of the "medical" sector.
Vigil Neuroscience (NASDAQ:VIGL) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.
Vigil Neuroscience has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
Vigil Neuroscience presently has a consensus price target of $17.20, suggesting a potential upside of 368.66%. Omega Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 332.90%. Given Omega Therapeutics' higher probable upside, equities research analysts plainly believe Vigil Neuroscience is more favorable than Omega Therapeutics.
83.6% of Vigil Neuroscience shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 33.0% of Vigil Neuroscience shares are held by insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Vigil Neuroscience has a net margin of 0.00% compared to Vigil Neuroscience's net margin of -1,868.35%. Omega Therapeutics' return on equity of -64.96% beat Vigil Neuroscience's return on equity.
Omega Therapeutics received 5 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 75.00% of users gave Vigil Neuroscience an outperform vote while only 71.88% of users gave Omega Therapeutics an outperform vote.
In the previous week, Vigil Neuroscience had 11 more articles in the media than Omega Therapeutics. MarketBeat recorded 29 mentions for Vigil Neuroscience and 18 mentions for Omega Therapeutics. Omega Therapeutics' average media sentiment score of 0.78 beat Vigil Neuroscience's score of 0.36 indicating that Vigil Neuroscience is being referred to more favorably in the media.
Vigil Neuroscience has higher earnings, but lower revenue than Omega Therapeutics. Vigil Neuroscience is trading at a lower price-to-earnings ratio than Omega Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Omega Therapeutics beats Vigil Neuroscience on 10 of the 17 factors compared between the two stocks.
Get Omega Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omega Therapeutics Competitors List
Related Companies and Tools
